📣 VC round data is live. Check it out!
- Public Comps
- Bionano Genomics
Bionano Genomics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bionano Genomics and similar public comparables like Arcoma, Clinical Laserthermia, Boule Diagnostics, Observe Medical and more.
Bionano Genomics Overview
About Bionano Genomics
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
Founded
2007
HQ

Employees
100
Website
Financials (LTM)
EV
$17M
Valuation Multiples
Start free trialBionano Genomics Financials
Bionano Genomics reported last 12-month revenue of $30M.
In the same LTM period, Bionano Genomics generated $14M in gross profit and had net loss of ($28M).
Revenue (LTM)
Bionano Genomics P&L
In the most recent fiscal year, Bionano Genomics reported revenue of $29M and EBITDA of ($16M).
Bionano Genomics is unprofitable as of last fiscal year, with gross margin of 46%, EBITDA margin of (57%), and net margin of (93%).
Financial data powered by Morningstar, Inc.
Bionano Genomics Stock Performance
Bionano Genomics has current market cap of $14M, and enterprise value of $17M.
Market Cap Evolution
Bionano Genomics' stock price is $1.25.
Bionano Genomics share price increased by 7.3% in the last 30 days, and decreased by 65.9% in the last year.
Bionano Genomics has an EPS (earnings per share) of $-2.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17M | $14M | 0.8% | 7.3% | 8.7% | -65.9% | $-2.30 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBionano Genomics Valuation Multiples
Bionano Genomics trades at 0.6x EV/Revenue multiple, and (1.0x) EV/EBITDA.
EV / Revenue (LTM)
Bionano Genomics Financial Valuation Multiples
As of May 23, 2026, Bionano Genomics has market cap of $14M and EV of $17M.
Bionano Genomics has a P/E ratio of (0.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bionano Genomics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Bionano Genomics Margins & Growth Rates
Bionano Genomics grew revenue by 13% and net profit by 16% in the last fiscal year.
In the most recent fiscal year, Bionano Genomics reported gross margin of 46%, EBITDA margin of (57%), and net margin of (93%).
Bionano Genomics Margins
Bionano Genomics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Bionano Genomics Operational KPIs
Bionano Genomics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.5M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Bionano Genomics Competitors
Bionano Genomics competitors include Arcoma, Clinical Laserthermia, Boule Diagnostics, Observe Medical, Conneqt Health, ViroGates, Advanced Medical, Scandinavian Real Heart, Labo Euromedis and Scandinavian Medical.
Most Bionano Genomics public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.8x | 0.8x | 7.5x | 7.1x | |||
| 6.8x | 5.3x | (4.5x) | (4.7x) | |||
| 0.7x | 0.7x | 7.5x | 8.9x | |||
| 8.6x | — | (5.4x) | — | |||
| 6.8x | 7.4x | (1.4x) | — | |||
| 9.3x | — | (8.0x) | — | |||
| 64356.9x | — | 3799.8x | — | |||
| — | — | (3.9x) | — | |||
This data is available for Pro users. Sign up to see all Bionano Genomics competitors and their valuation data. Start Free Trial | ||||||
Bionano Genomics Funding History
Before going public, Bionano Genomics raised $120M in total equity funding, across 5 rounds.
Bionano Genomics Funding Rounds
Bionano Genomics M&A Activity
Bionano Genomics has acquired 3 companies to date.
Last acquisition by Bionano Genomics was on November 28th 2022. Bionano Genomics acquired Purigen Biosystems for $64M (EV/Revenue multiple of ).
Latest Acquisitions by Bionano Genomics
| Description | Purigen Biosystems is a Pleasanton-based biotechnology firm specializing in nucleic acid purification using isotachophoresis technology. The Ionic Purification System processes DNA and RNA from challenging samples like FFPE tissues and low-input cells without surface binding, yielding high-quality extracts for next-generation sequencing. Adopted by academic labs and pharma researchers worldwide, the platform launched commercially in 2020 following Series A funding. | BioDiscovery is an El Segundo, California-based scientific software provider for genomic analysis and genetic research. Its NGI software suite supports NGS data visualization, CNV detection, and structural variant calling for array and sequencing platforms. Used by over 1,000 labs worldwide, including NIH-funded projects, the tools integrate with Illumina and Affymetrix systems. Established in 2007, BioDiscovery also offers consulting for cytogenetics workflows. | Lineagen is a molecular diagnostics company specializing in genetic testing for neurodevelopmental disorders like autism spectrum disorder, multiple sclerosis, and chronic obstructive pulmonary disease. Salt Lake City-headquartered, it leverages the University of Utah's Population Database to identify biomarkers and develop tests such as the INFINITEST array for early childhood screening. Founded in 2002, Lineagen offers comprehensive genetic counseling alongside its assays, aiding clinicians in personalized treatment plans. The company commercializes proprietary research into diagnostic panels targeting complex diseases influenced by genetics. |
| HQ Country | |||
| HQ City | San Francisco, CA | Ann Arbor, MI | Salt Lake City, UT |
| Deal Date | 28 Nov 2022 | 12 Oct 2021 | 24 Aug 2020 |
| Valuation | $64M | $100M | $10M |
| EV/Revenue | |||
| EV/EBITDA | |||
This data is available for Pro users. Sign up to see all Bionano Genomics acquisitions and their M&A valuation multiples. Start Free Trial | |||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bionano Genomics
| When was Bionano Genomics founded? | Bionano Genomics was founded in 2007. |
| Where is Bionano Genomics headquartered? | Bionano Genomics is headquartered in United States. |
| How many employees does Bionano Genomics have? | As of today, Bionano Genomics has over 100 employees. |
| Who is the CEO of Bionano Genomics? | Bionano Genomics' CEO is R. Erik Holmlin. |
| Is Bionano Genomics publicly listed? | Yes, Bionano Genomics is a public company listed on Nasdaq. |
| What is the stock symbol of Bionano Genomics? | Bionano Genomics trades under BNGO ticker. |
| When did Bionano Genomics go public? | Bionano Genomics went public in 2018. |
| Who are competitors of Bionano Genomics? | Bionano Genomics main competitors include Arcoma, Clinical Laserthermia, Boule Diagnostics, Observe Medical, Conneqt Health, ViroGates, Advanced Medical, Scandinavian Real Heart, Labo Euromedis, Scandinavian Medical. |
| What is the current market cap of Bionano Genomics? | Bionano Genomics' current market cap is $14M. |
| What is the current revenue of Bionano Genomics? | Bionano Genomics' last 12 months revenue is $30M. |
| What is the current revenue growth of Bionano Genomics? | Bionano Genomics revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of Bionano Genomics? | Current revenue multiple of Bionano Genomics is 0.6x. |
| Is Bionano Genomics profitable? | No, Bionano Genomics is not profitable. |
| What is the current net income of Bionano Genomics? | Bionano Genomics' last 12 months net income is ($28M). |
| How many companies Bionano Genomics has acquired to date? | As of May 2026, Bionano Genomics has acquired 3 companies. |
| What was the largest acquisition by Bionano Genomics? | $100M acquisition of BioDiscovery on 12th October 2021 was the largest M&A Bionano Genomics has done to date. |
| What companies Bionano Genomics acquired? | Bionano Genomics acquired BioDiscovery, Purigen Biosystems, and Lineagen. |
| In how many companies Bionano Genomics has invested to date? | Bionano Genomics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Bionano Genomics
Lists including Bionano Genomics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
